FAM117A

Across TCGA pan-cancer cohorts, FAM117A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM117A data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM117A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM117A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where FAM117A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.575	0.270	.001	31	view →
GBM	OS	Median	All	0.258	0.797	.035	14	view →
LUAD	OS	Tertile	III,IV	0.815	0.359	.011	11	view →
UCEC	DFS	Tertile	All	1.000	0.852	.017	4	view →
CCRCC	DFS	Tertile	III,IV	0.700	0.257	.020	4	view →
HNSC	DFS	Tertile	IV	0.405	1.000	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM117A–PDAC (DFS)

Open the PDAC breakdown →